Silverback Asset Management Invests $1.55M in NeoGenomics

Institutional investor takes stake in medical research company

Mar. 14, 2026 at 10:06am

Got story updates? Submit your updates here. ›

Silverback Asset Management LLC has purchased 201,313 shares of NeoGenomics, Inc. (NASDAQ:NEO), a medical research company, valued at approximately $1.55 million. The investment represents around 0.16% ownership of NeoGenomics.

Why it matters

The investment by Silverback Asset Management, a prominent institutional investor, signals confidence in NeoGenomics' business and growth potential. As a leading provider of cancer-focused genetic and molecular testing services, NeoGenomics' performance is closely watched by the investment community.

The details

According to a recent SEC filing, Silverback Asset Management acquired the stake in NeoGenomics during the third quarter. The firm now owns approximately 0.16% of the medical research company's outstanding shares.

  • Silverback Asset Management purchased the shares in the third quarter of the year.

The players

Silverback Asset Management LLC

An institutional investment firm that has taken a position in NeoGenomics, Inc.

NeoGenomics, Inc.

A leading provider of cancer-focused genetic and molecular testing services, traded on the Nasdaq under the symbol NEO.

Got photos? Submit your photos here. ›

The takeaway

The investment by Silverback Asset Management underscores the potential that institutional investors see in NeoGenomics' cancer diagnostics business. As the company continues to grow its services and market share, further investments and analyst attention are likely to follow.